Thus, the interaction between PD-1 and its ligands, especially PD-L1, may contribute to the immune suppression of the tumor microenvironment, and therefore, blockade of this pathway is a potential approach to promising immunotherapy for cancers [22]. The gene discussed is PDCD1; the disease is neoplasm.